MedTrace Logo

Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data

NCT06199934 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19853610

Last updated 2025-09-10

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to learn about how well different versions of the Pfizer-BioNTech COVID-19 vaccine (called BNT162b2) work at preventing death, severe COVID-19 that requires a trip to the hospital, and overall use of healthcare resources, such as needing to go the doctor or urgent care due to illness. Pfizer is not enrolling any participants for this study. Instead, existing data from different health data sources will be used to help answer the scientific questions Pfizer is interested in learning more about.

Conditions

Interventions

BIOLOGICAL

Vaccination

BNT162b2 vaccination

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-11
Primary Completion
2024-07-31
Completion
2024-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06199934 on ClinicalTrials.gov